Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.
Smaldone
L
L
Bristol-Myers Squibb, Pharmaceutical Research Institute, Wallingford, CT 06492-7660.
Plezia
P
P
Alberts
D
D
Aapro
M
M
Sartiano
G
G
Dorn
M
M
Brady
M
M
Comerski
C
C
Schwartz
S E
SE
Fairchild
C
C
D000818:Animals; D000932:Antiemetics / Q000493:pharmacokinetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D004285:Dogs; D018492:Dopamine Antagonists; D005260:Female; D005289:Ferrets; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D051381:Rats; D012702:Serotonin Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D018492:Dopamine Antagonists; D012702:Serotonin Antagonists; C060190:batanopride; D008787:Metoclopramide; D002945:Cisplatin